Indexado en

Licencia y uso

Citaciones

Cited 76 times in

Cited 63 times in

Altmetrics

Grant support

Funding PS has received funding funding from the Carlos III (FIS) Health Institute PI16/01433 and PI21/00197, Asociacion Es-panola contra el Cancer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800) .

Análisis de autorías institucional

Compartir

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Publicado en:HAEMATOLOGICA 108 (1): 110-121 - 2023-01-01 108(1), DOI: 10.3324/haematol.2022.280805

Autores: Kwon, Mi; Iacoboni, Gloria; Reguera, Juan Luis; Corral, Lucia Lopez; Morales, Rafael Hernani; Ortiz-Maldonado, Valentin; Guerreiro, Manuel; Caballero, Ana Carolina; Dominguez, Maria Luisa Guerra; Pina, Jose Maria Sanchez; Bastos-Oreiro, Mariana; Catala, Eva; Delgado, Javier; Henriquez, Hugo Luzardo; Calbacho, Maria; Bailen, Rebeca; Carpio, Cecilia; Sureda, Anna; Briones, Javier; Hernandez-Boluda, Juan Carlos; Cebrian, Nuria Martinez; Martin, Jose Luis Diez; Martin, Alejandro; Barba, Pere

Afiliaciones

Resumen

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P=0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P=0.003, and 42% vs. 16%, P= 2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those re-ceiving tisa-cel. Efficacy was not significantly different between both products.

Palabras clave